Philip Hemme, Author at Labiotech.eu

About

Young French-German Entrepreneur, Co-founder & CEO of Labiotech.eu. High-level table tennis player, and German beer/French Wine lover 🙂

Articles by Philip Hemme

News and Trends 30 Nov 2015

Cellectis’ CEO: “I’m just trying to be realistic, CAR-T is not THE miracle cure for Cancer”

CAR-T is solidifying in everybody’s mind as the next revolution in Cancer treatment. But there is still a lot to do…That’s basically what came out from my discussion with André Choulika, the CEO of the French CAR-T miracle Cellectis. Cellectis is probably the most successful Biotech in France. It was founded in 1999 by Choulika […]

November 30, 2015 - 5 minutesmins - By Philip Hemme

News and Trends 28 Nov 2015

What happened this week? Boston Pharmaceuticals, Biosimilars, Adaptimmune

Monday: First Investment by the Former CEO of Sanofi? Just a €560M Virtual Biotech… #Easy Tuesday: 2015 Review: What Exciting Developments Have Been Made in Neurodegenerative Disease? Wednesday: Novartis Attacks Amgen. Amgen wants to Ruin Roche – The New Biosimilar War! Thursday: A €1.3M Start-Up is Engineering Baker’s Yeast to Make Green House Gases Useful Friday: Could this new […]

November 28, 2015 - 1 minutemin - By Philip Hemme

News and Trends 27 Nov 2015

Biotech of the week: PsiOxus, “non-traditional” Immuno-oncology from Oxford

This week we leave Ireland and head South-East across the Irish Sea where we arrive at the ancient city of Oxford, our location of interest. ‘The city of dreaming spires’ is known for it’s world famous university, the Shark House (if you don’t know it, have a search, you won’t regret it :p) and the location for […]

November 27, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 23 Nov 2015

Finally, Pfizer acquires Botox-maker Allergan for €150Bn to move to tax-friendly Ireland!

The Rumor became more and more tangleon what is now the biggest Pharma deal ever. The Rumor was pumped up by reports from Bloomberg and CNBC, saying the deal could be closed on Monday, as we reported here. And now it’s official. Just a few hours ago, Pfizer announced it agrees on buying Allergan for €150Bn […]

November 23, 2015 - 1 minutemin - By Philip Hemme

News and Trends 21 Nov 2015

What happened this week? Genfit, History of Biotech, Cellectis

Monday: Interview with the CEO of Genfit – The Billion Euro Liver Biotech on its phase III NASH Drug Tuesday: History of Biotech: How Modern Biotechnology Started-Up 39 Years Ago Wednesday: The UK Catapults Cell Therapy Manufacture into Europe with a €78.5M New Facility Thursday: Why has the Universal CAR-T Treatment For Leukemia Hooked TWO Big Pharmas […]

November 21, 2015 - 1 minutemin - By Philip Hemme

News and Trends 20 Nov 2015

Biotech of the week: Opsona Therapeutics, The Leading Irish Immuno-Oncology Biotech

This week we say farewell to Austria and head North-West, across the United Kingdom and land in the Emerald Isle, Ireland, where we arrive at our destination, Dublin. The capital city of Ireland is the home of the very famous Irish dry stout, Trinity College (plus its stunning library) and a nearly 900-year-old cathedral. It is […]

November 20, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 19 Nov 2015

“The Next Generation of Biologicals will be Cell-based”

That’s what Zami Aberman, CEO of one of the world-leading cell-therapy company Pluristem told me during our lunch at Berlin this week. An enthusiastic statement for a sector that could indeed be the next blockbuster after the monoclonal antibodies. Pluristem is an Israel based Biotech company developing off-the-shelf cell therapies for a variety of human diseases. What makes […]

November 19, 2015 - 6 minutesmins - By Philip Hemme

News and Trends 19 Nov 2015

This 10,000 Employee French Pharma is Finally Entering the Biotech Partnership Race

Biotech is getting more and more about partnering rather than doing everything alone. Some conservative Pharmas, which worked to more of a ‘Silo model’, are now branching out in a more open approach; the last one being the Pharma company from the south-west of France Pierre Fabre. The company, named after its iconic founder Pierre Fabre, […]

November 19, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 16 Nov 2015

What are Money-Magnet Moderna’s future plans? French Founding CEO explains here

Before the end of the mRNA conference in Berlin, I had to interview Stephane Bancel, the French founding CEO of Moderna…one of the biggest deals in Biotech today. Moderna is the mRNA therapies companies from Cambridge/Boston (US), most famous for having raised over 900 million dollars in VC money. I met Stephane one and a […]

November 16, 2015 - 1 minutemin - By Philip Hemme

News and Trends 14 Nov 2015

What happened this week? mRNA Therapies, TCR & Algae Beer

Monday: Leading TCR Immuno-oncology Biotech shows Promising Results against Cancer Tuesday: What the FUGT? We tried the Algae Bar Beer for the TransArt Fest in Copenhagen! Wednesday: Using Algae and NanoTech to Kill Cancer: An Australian-German Collaboration Thursday (two interviews): Interview: The ‘RNA’ People’s Pioneering Strategy to get mRNA Therapies onto the Market EU’s Largest Private […]

November 14, 2015 - 1 minutemin - By Philip Hemme

News and Trends 13 Nov 2015

We were at the Berlin Office Opening of the Leading German Bioinformatics Company

Berlin is hotspot which is always attracting companies in the Biotech field (including us :p). Molecular Health is a 150-strong Bioinformatic company from Heidelberg (Germany) which has also decided to open an office in the capital, to profit from its proximity to the political system. The opening took place in the new office, which was […]

November 13, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 13 Nov 2015

Biotech of the Week: Lexogen and it’s Transcriptomic Approach to Disease

This week we say ‘bye for noo’ to Edinburgh and head South East, across the English Channel and through both Netherlands and Germany where we arrive at this week’s destination, Vienna, Austria. This country is the place of birth of Mozart, has the only cuisine named after a city (Viennese) and absolutely stunning scenery, it is […]

November 13, 2015 - 2 minutesmins - By Philip Hemme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Philip Hemme

About

Articles by Philip Hemme

Cellectis’ CEO: “I’m just trying to be realistic, CAR-T is not THE miracle cure for Cancer”

What happened this week? Boston Pharmaceuticals, Biosimilars, Adaptimmune

Biotech of the week: PsiOxus, “non-traditional” Immuno-oncology from Oxford

Finally, Pfizer acquires Botox-maker Allergan for €150Bn to move to tax-friendly Ireland!

What happened this week? Genfit, History of Biotech, Cellectis

Biotech of the week: Opsona Therapeutics, The Leading Irish Immuno-Oncology Biotech

“The Next Generation of Biologicals will be Cell-based”

This 10,000 Employee French Pharma is Finally Entering the Biotech Partnership Race

What are Money-Magnet Moderna’s future plans? French Founding CEO explains here

What happened this week? mRNA Therapies, TCR & Algae Beer

We were at the Berlin Office Opening of the Leading German Bioinformatics Company

Biotech of the Week: Lexogen and it’s Transcriptomic Approach to Disease

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Philip Hemme

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!